Neurocrine Biosciences (NBIX) Revenue Growth (1y) (2011 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | 6.60% |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | 10.16% |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | 5.07% |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | 2.52% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 2.60% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 19.16% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | 37.72% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | -1.92% |
| 10 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | 39.49% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39.49% |
| Mar 31, 2026 | 42.25% |
| Dec 31, 2025 | 28.33% |
| Sep 30, 2025 | 27.78% |
| Jun 30, 2025 | 16.49% |
| Mar 31, 2025 | 11.12% |
| Dec 31, 2024 | 21.84% |
| Sep 30, 2024 | 24.72% |
| Jun 30, 2024 | 30.37% |
| Mar 31, 2024 | 22.57% |
| Dec 31, 2023 | 25.05% |
| Sep 30, 2023 | 28.59% |
| Jun 30, 2023 | 19.70% |
| Mar 31, 2023 | 35.35% |
| Dec 31, 2022 | 32.05% |
| Sep 30, 2022 | 31.05% |
| Jun 30, 2022 | 30.91% |
| Mar 31, 2022 | 31.28% |
| Dec 31, 2021 | 25.86% |
| Sep 30, 2021 | 14.51% |